Safety is especially important when considering higher doses, as these may increase the likelihood of side effects
Serious side effects may include pancreatitis, gallstones, low blood sugar (hypoglycemia), kidney problems including kidney failure, changes in vision in people with type 2 diabetes, increased resting heart rate, depression or thoughts of suicide
In the increasingly competitive GLP-1 market, Novo Nordisk has continued to explore and expand the boundaries of Semaglutide's indications, with multiple clinical launches in NASH, AD, HFpEF, DR, PAD, and other indications
Multiple studies demonstrate reduced smoking and nicotine dependence with TMS, leading to the 2020 FDA clearance for the BrainsWay Deep TMS system as an aid for smoking cessation
Scholarly Commons, Emory Law